Nabi kept by Thomas Weisel at peer perform

Nabi Biopharmaceuticals Inc. was maintained by Thomas Weisel Partners analyst Joe Slavinsky at a peer perform rating on news the company has been awarded a $4.1 million grant from the National Institute on Drug Abuse, a division of the National Institutes of Health, for its NicVAX vaccine being developed to treat nicotine addiction. Nabi shares Tuesday were up $0.37, or 2.70%, at $14.08 on volume of 879,155 shares versus the three-month running average of 722,288 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.